Faeth Therapeutics adds Zymeworks R&D chief Adam Schayowitz to board
The company expanded its board to seven members and named Schayowitz a Class III director effective October 23, 2026.
SEC filing
Latest
2 stories
Sign inSign in2 stories
The company expanded its board to seven members and named Schayowitz a Class III director effective October 23, 2026.
SEC filing